Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Vomiting 13Nausea 11Neoplasms 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Rectal Neoplasms 2Multiple Myeloma 2Lung Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Radiation Injuries 1Pancreatic Neoplasms 1Pain 1Neoplasms, Germ Cell and Embryonal 1Nausea With Vomiting Chemotherapy-Induced 1Lymphoma, Non-Hodgkin 1Lymphoma 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia 1Hematologic Neoplasms 1Hematologic Diseases 1Glioma 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Brain Neoplasms 1Bile Duct Neoplasms 1Appendiceal Neoplasms 1

Interventions

Cisplatin 8Etoposide 6Paclitaxel 5Ifosfamide 4Sunitinib 3Oxaliplatin 3Cyclophosphamide 3Brentuximab Vedotin 3tremelimumab 2pembrolizumab 2etoposide phosphate 2durvalumab 2Sirolimus 2Gemcitabine 2Everolimus 2Epirubicin 2Dexamethasone 2Carboplatin 2Bleomycin 2Bevacizumab 2tozuleristide 1rolapitant 1ribociclib 1pegfilgrastim 1pazopanib 1olaparib 1fosaprepitant 1fludarabine phosphate 1fludarabine 1cabozantinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms, Germ Cell and Embryonal × Palonosetron × Clear all
NCT03960151 2019-05-22

Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy

Hoosier Cancer Research Network

Phase 2 Withdrawn

Neoplasms, Germ Cell and Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡